Zymergen Inc. Stock Research

ZY Stock Price

ZY RSI Chart

ZY Valuation

Market Cap

252.3M

Price/Earnings (Trailing)

-0.69

Price/Sales (Trailing)

17.35

EV/EBITDA

-0.12

Price/Free Cashflow

-0.96

ZY Price/Sales (Trailing)

ZY Profitability

EBT Margin

-2508.64%

Return on Equity

-154.23%

Return on Assets

-77.49%

Free Cashflow Yield

-103.8%

ZY Fundamentals

ZY Revenue

Revenue (TTM)

14.5M

Revenue Y/Y

-55.01%

Revenue Q/Q

-45.02%

ZY Earnings

Earnings (TTM)

-365.0M

Earnings Y/Y

-15.47%

Earnings Q/Q

-61.5%

Price Action

Last 7 days

-8.6%

Last 30 days

-8.6%

Last 90 days

13.0%

Trailing 12 Months

-80.7%

ZY Financial Health

Current Ratio

4.59

ZY Investor Care

Shares Dilution (1Y)

33.68%

Diluted EPS (TTM)

-3.28

Financials for Zymergen

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-18.1%	14,546,000	17,766,000	16,743,000	19,577,000	18,703,000
S&GA Expenses	-23.2%	15,668,000	20,414,000	23,648,000	22,903,000	23,280,000
R&D Expenses	-12.8%	129,082,000	148,048,000	159,120,000	158,902,000	141,532,000
EBITDA	-2.6%	-316,699,000	-308,651,000	-326,334,000	-329,757,000	-
EBITDA Margin	-25.6%	-21.77	-17.34	-19.49	-16.82	-
Earnings Before Taxes	-4.5%	-364,907,000	-349,332,000	-361,734,000	-359,251,000	-322,816,000
EBT Margin	-27.8%	-25.09	-19.63	-21.61	-18.32	-
Interest Expenses	33.0%	26,634,000	20,023,000	14,705,000	11,081,000	11,041,000
Net Income	-4.5%	-364,951,000	-349,349,000	-361,785,000	-359,278,000	-322,865,000
Net Income Margin	-27.8%	-25.09	-19.63	-21.61	-18.32	-
Free Cahsflow	10.8%	-261,881,000	-293,725,000	-335,905,000	-326,940,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Assets	-23.8%	471	618	522	627	725
Current Assets	-32.2%	240	354	407	517	606
Cash Equivalents	-36.6%	214	337	386	496	578
Inventory	1.9%	6.00	6.00	6.00	6.00	6.00
Net PPE	26.0%	71.00	56.00	54.00	55.00	62.00
Goodwill	-100.0%	-	41.00	41.00	34.00	34.00
Liabilities	-14.5%	234	274	114	151	156
Current Liabilities	-41.0%	52.00	88.00	74.00	121	52.00
LT Debt, Current	-100.0%	-	51.00	44.00	80.00	-
LT Debt, Non Current	NaN%	-	-	-	80.00	-
Shareholder's Equity	-31.2%	237	344	408	477	569
Retained Earnings	-10.3%	-1,324	-1,200	-1,135	-1,057	-959
Additional Paid-In Capital	0.6%	1,561	1,552	1,544	1,534	1,528
Accumulated Depreciation	5.0%	83.00	79.00	78.00	73.00	56.00
Shares Outstanding	0.7%	104	103	103	102	78.00
Float	-	2,100	-	-	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Cashflow From Operations	11.1%	-234	-264	-302	-299	-272
Share Based Compensation	6.3%	28.00	26.00	21.00	16.00	12.00
Cashflow From Investing	5.3%	-26.74	-28.24	-32.20	-26.03	-22.27
Cashflow From Financing	-119.4%	-98.78	510	514	746	850

Risks for ZY

What is the probability of a big loss on ZY?

96.2%

Probability that Zymergen stock will be more than 20% underwater in next one year

96.2%

Probability that Zymergen stock will be more than 30% underwater in next one year.

81.0%

Probability that Zymergen stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zymergen was unfortunately bought at previous high price.

Drawdowns

Returns for ZY

Cumulative Returns on ZY

Which funds bought or sold ZY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	sold off	-100	-261,000	-	-%
2023-03-10	BAILLIE GIFFORD & CO	sold off	-100	-7,845,000	-	-%
2023-02-15	JANE STREET GROUP, LLC	sold off	-100	-106,000	-	-%
2023-02-15	NOMURA HOLDINGS INC	sold off	-100	-39,000	-	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	sold off	-100	-41,000	-	-%
2023-02-15	McIlrath & Eck, LLC	sold off	-100	-	-	-%
2023-02-14	LMR Partners LLP	sold off	-100	-80,000	-	-%
2023-02-14	PLUSTICK MANAGEMENT LLC	sold off	-100	-1,946,000	-	-%
2023-02-14	Man Group plc	sold off	-100	-28,000	-	-%
2023-02-14	Bill & Melinda Gates Foundation	sold off	-100	-200,000	-	-%

Latest Funds Activity

Are funds buying ZY calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ZY

No. of Funds

Zymergen News

Schedule 13G FIlings of Zymergen

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 21, 2022	sb investment advisers (uk) ltd	0.0%	0	SC 13G/A
Feb 14, 2022	sb investment advisers (uk) ltd	26.0%	26,614,219	SC 13G
Feb 14, 2022	data collective ii, l.p.	2.4%	2,448,901	SC 13G
Feb 11, 2022	gic private ltd	4.96%	5,078,902	SC 13G/A
Feb 11, 2022	true ventures iv, l.p.	2.6%	2,659,857	SC 13G

ZY Fair Value

Latest Insider Trading transactions for ZY

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-10-19	Ocko Matthew	back to issuer	-	-	-7,366,630	-
2022-10-19	SVF Excalibur (Cayman) Ltd	sold	-	-	-26,614,200	-
2022-10-19	Serber Zachariah	back to issuer	-	-	-2,551,680	-
2022-10-19	Gorjanc Christine Marie	back to issuer	-	-	-50,000	-
2022-10-19	Serber Zachariah	back to issuer	-	-	-40,000	-
2022-10-19	FLATLEY JAY T	back to issuer	-	-	-144,789	chairman and acting ceo
2022-10-19	PETERSON SANDRA E	back to issuer	-	-	-119,119	-
2022-10-19	Singh Enakshi	back to issuer	-	-	-462,241	chief financial officer
2022-10-19	Murdoch Travis	back to issuer	-	-	-79,697	-
2022-10-19	Chu Steven	back to issuer	-	-	-50,000	-

About Zymergen

Jay T. Flatley

www.zymergen.com

510

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.

ZY Income Statement

2022-06-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues	$ 2,634	$ 5,854	$ 7,425	$ 9,589
Cost and operating expenses:
Research and development	31,186	50,152	59,925	89,963
Sales and marketing	3,158	7,904	6,796	14,776
General and administrative	24,294	23,661	47,999	42,992
Goodwill impairment charge	40,645	0	40,645	0
Restructuring charges (benefit)	(185)	0	(315)	0
Total cost and operating expenses	108,830	103,546	177,237	190,690
Operating loss	(106,196)	(97,692)	(169,812)	(181,101)
Other income (expense):
Interest income	2	12	53	55
Interest expense	(9,378)	(2,767)	(17,423)	(5,494)
Gain (loss) on change in fair value of warrant liabilities	0	(430)	0	1,849
Other expense, net	(885)	(5)	(1,417)	(768)
Total other expense	(10,261)	(3,190)	(18,787)	(4,358)
Loss before income taxes	(116,457)	(100,882)	(188,599)	(185,459)
Benefit from (provision for) income taxes	(11)	16	15	8
Net loss and comprehensive loss	(116,468)	(100,866)	(188,584)	(185,451)
Net loss and comprehensive loss	$ (116,468)	$ (100,866)	$ (188,584)	$ (185,451)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.13)	$ (1.30)	$ (1.83)	$ (4.07)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.13)	$ (1.30)	$ (1.83)	$ (4.10)
Weighted average shares used in computing net loss per share to common stockholders, basic (in shares)	103,482,907	77,671,643	103,297,070	45,512,654
Weighted average shares used in computing net loss per share to common stockholders, diluted (in shares)	103,482,907	77,671,643	103,297,070	45,727,153
Revenues from research and development service agreements
Revenues	$ 1,191	$ 4,846	$ 4,412	$ 7,460
Collaboration and other revenue
Revenues	746	1,008	2,079	2,129
Automation revenue
Revenues	480	0	480	0
Cost and operating expenses:
Cost of revenue	637	0	637	0
Grant revenue
Revenues	217	0	454	0
Service revenue
Cost and operating expenses:
Cost of revenue	$ 9,095	$ 21,829	$ 21,550	$ 42,959

ZY Balance Sheet

2022-06-30

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Current assets:

Cash and cash equivalents

$ 213,558

$ 386,105

^[1]

Accounts receivable

1,272

520

^[1]

Accounts receivable, unbilled

2,424

2,565

^[1]

Prepaid expenses

11,814

7,818

^[1]

Inventories

6,107

6,035

^[1]

Restricted cash, current

2,997

2,105

^[1]

Other current assets

1,469

2,201

^[1]

Total current assets

239,641

407,349

^[1]

Restricted cash

10,016

9,849

^[1]

Property and equipment, net

70,590

53,799

^[1]

Operating lease right-of-use assets

141,105

Goodwill

40,645

^[1]

Intangible assets, net

7,380

8,529

^[1]

Other long-term assets

2,236

2,225

^[1]

Total assets

470,968

522,396

^[1]

Current liabilities:

Accounts payable

12,877

5,418

^[1]

Accrued and other liabilities

27,009

17,496

^[1]

Short-term operating lease liabilities

7,900

Short-term debt, net

43,953

^[1]

Short-term deferred rent

2,218

^[1]

Deferred revenue

4,410

4,468

^[1]

Total current liabilities

52,196

73,553

^[1]

Long-term operating lease liabilities

178,181

Long-term deferred rent

35,390

^[1]

Other long-term liabilities

3,968

4,967

^[1]

Total liabilities

234,345

113,910

^[1]

Commitments and contingencies

^[1]

Stockholders' equity

Preferred stock, $0.001 par value, 170,000,000 authorized as of June 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

^[1]

Common stock, $0.001 par value, 1,500,000,000 shares authorized as of June 30, 2022 and December 31, 2021, respectively; 103,828,096 and 103,045,299 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

104

103

^[1]

Additional paid-in capital

1,560,628

1,543,908

^[1]

Accumulated deficit

(1,324,109)

(1,135,525)

^[1]

Total stockholders' equity

236,623

408,486

^[1]

Total liabilities and stockholders' equity

$ 470,968

$ 522,396

^[1]

Preferred stock, par value (in dollars per share)

$ 0.001

[1]	The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date.